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A unit risk factor (URF) was developed for isoprene based on evaluation of three animal studies with
adequate data to perform doseeresponse modeling (NTP, 1994, 1999; Placke et al., 1996). Ultimately, the
URF of 6.2E-08 per ppb (2.2E-08 per mg/m3) was based on the 95% lower conﬁdence limit on the effective
concentration corresponding to 10% extra risk for liver carcinoma in male B6C3F1 mice after incorpo-
rating appropriate adjustment factors for species differences in target tissue metabolite concentrations
and inhalation dosimetry. The corresponding lifetime air concentration at the 1 in 100,000 no signiﬁcant
excess risk level is 160 ppb (450 mg/m3). This concentration is almost 4400 times lower than the lowest
exposure level associated with statistically increased liver carcinoma in B6C3F1 mice in the key study
(700 ppm in Placke et al., 1996) and is above typical isoprene breath concentrations reported in the
scientiﬁc literature. Continuous lifetime environmental exposure to the 1 in 100,000 excess risk level of
160 ppb would be expected to raise the human blood isoprene area under the curve (AUC) less than one-
third of the standard deviation of the endogenous mean blood AUC. The mean for ambient air monitoring
sites in Texas (2005e2014) is approximately 0.13 ppb.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Isoprene is the 2-methyl analog of 1,3-butadiene. It is used
largely in the manufacturing of synthetic rubber (e.g., for vehicle
tires). It is also used in the manufacturing of styrene-isoprene-
styrene block co-polymers and butyl rubber, in the production of
hydrocarbon resins, and for the synthesis of terpenes (BG Chemie,
2000; Melnick et al., 1996; Sharkey, 1996). Anthropogenic sources
of isoprene include: petroleum cracking, ethylene production (by-
product), wood pulp production, oil ﬁres, tobacco smoke, and
automobile exhaust (Hurst, 2007; Melnick et al., 1996; Sharkey,
1996).
Isoprene is also produced naturally by plants (isoprene
biosynthesis is associated with photosynthesis), animals, and bac-
teria. The amount of isoprene produced naturally far exceeds that
which is produced synthetically. It is the underlying structure of
isoprenoid biochemicals such as cholesterol, carotenoids, and
vitamin A (Hurst, 2007; Song et al., 2004). Greater than 200(J.T. Haney), Tracie.Phillips@
.L. Sielken), Ciriacov@tamu.
Inc. This is an open access article udifferent plant species, especially trees, emit isoprene (Loreto,
1997). Isoprene accounts for more than half of natural volatile
organic compound (VOC) emissions. U.S. woodlands produce an
estimated 3mg/m2 compared to about 5mg/m2 per hour total VOC,
with the south central and southeastern areas of the U.S. having the
highest biogenic emissions. Emissions are seasonal (highest in the
summer) since isoprene is primarily emitted by deciduous trees
(Guenther et al., 1994, 1995 and Fuentes andWang, 1999 as cited by
NTP, 2014). The tree species with the highest isoprene emissions
are generally in the genera Quercus (oaks) and Populus (poplars),
with Picea (spruces) being the only conifer isoprene emitters
(Logan et al., 2000). In addition to emissions from trees, foods are
expected to be a daily source of exposure since agricultural crops
emit isoprene and it is the basic structural unit in many natural
products found in consumed foods (e.g., terpenes, vitamins A and K,
carrots, coffee, essential oil of oranges) (NTP, 2014).
Humans produce isoprene endogenously at a rate of 0.15 mmol/
kg per hour, which is equivalent to 2e4 mg/kg-day, with blood
concentrations ranging from 1.0 to 4.8 mg/L (Taalman, 1996 and
Cailleux et al., 1992 as cited by NTP, 2014). In human breath,
isoprene has been found to be one of the main endogenous com-
pounds, accounting for up to 70% of exhaled hydrocarbons
(Gelmont et al., 1981 as cited by NTP, 2014). For example, MAKnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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337 volunteers. By comparison, annual averages at ambient air
monitoring sites in Texas range from not detected to 0.84 ppb, with
an approximate statewide mean and median of 0.13 and 0.07 ppb,
respectively (Texas Air Monitoring Information System (TAMIS)
data for 2005e2014). Generally, the major sources of isoprene in
ambient air appear to be biogenic emissions in rural areas and
vehicle emissions in urban areas (Borbon et al., 2001 and So and
Wang, 2004 as cited by NTP, 2014).
As stated previously, isoprene is the 2-methyl analog of 1,3-
butadiene, an industrial chemical that has been identiﬁed as an
animal and human carcinogen. According to the National Toxicity
Program's 13th Report on Carcinogens (NTP, 2014), isoprene is
“reasonably anticipated to be a human carcinogen” based on suf-
ﬁcient evidence of carcinogenicity from studies in experimental
animals (i.e., tumors at several different tissue sites in mice and
rats). For example, inhalation exposure to isoprene induced
increased incidences of neoplasms of the liver, lung, and hemato-
poietic system in mice (Placke et al., 1996). It is important for the
Texas Commission on Environmental Quality (TCEQ) to conduct an
inhalation carcinogenic doseeresponse assessment for isoprene
since:
 A carcinogenic doseeresponse assessment for inhalation expo-
sure to isoprene has not been conducted by human health
assessment programs such as the Integrated Risk Information
System (IRIS) of the U.S. Environmental Protection Agency
(USEPA) or the Ofﬁce of Environmental Health Hazard Assess-
ment (OEHHA) of the California Environmental Protection
Agency (CalEPA);
 The TCEQ performs carcinogenic doseeresponse assessments
for chemicals considered “likely to be carcinogenic to humans”,
particularly when a suitable doseeresponse assessment con-
ducted by another agency is not available for adoption (TCEQ,
2015);
 Isoprene is detected in ambient air and there are industrial point
sources of isoprene emissions in Texas that may increase
naturally-occurring ambient air concentrations in neighboring
communities; and
 A unit risk factor (URF) may be needed to help ensure the pro-
tection of public health.
Accordingly, a URF for isoprene has been developed based on
the evaluation of three laboratory animal studies with adequate
data to perform doseeresponse modeling (NTP, 1994, 1999; Placke
et al., 1996). The purpose of this paper is to present the procedures
used in the carcinogenic assessment of isoprene and the derivation
of the URF. The URF is then used to calculate the environmental air
concentration associated with the no signiﬁcant excess risk level of
1 in 100,000 assuming lifetime exposure (TCEQ, 2015).
2. Materials and methods
The TCEQ (2015) guidelines for carcinogenic assessment employ
the four-step risk assessment process formalized by the National
Research Council (NRC, 1983, 1994) and the procedures recom-
mended in the most recent USEPA cancer guidelines (USEPA,
2005a, 2005b) and scientiﬁc literature. For chronic adverse effects
determined or assumed (e.g., by default, due to a lack of sufﬁcient
carcinogenic MOA data to justify an alternative approach) to be
associatedwith linear doseeresponse relationships in the low-dose
region (typically cancer), the TCEQ adopts or derives URFs. In such
cases, a linear extrapolation is performed to estimate excess life-
time risk at lower doses, for example, through the calculation of a
point of departure (POD) using USEPA benchmark dose (BMD)software (version 3.4) to ﬁt data to a doseeresponse model. A
common POD for calculation of a URF is the 95% lower conﬁdence
limit on the effective concentration (EC) corresponding to 10% extra
risk (LEC10). The slope of the line from zero excess risk at zero
exposure to this POD is the inhalation URF (e.g., 0.1/LEC10 ¼ URF),
which may be described as the excess risk estimated to result from
continuous lifetime exposure to an agent on a per ppb or mg/m3 in
air basis (i.e., excess risk per ppb or mg/m3 assuming continuous
lifetime exposure).
While human studies are preferred for URF derivation under the
TCEQ (2015) guidelines, no human studies have evaluated the
relationship between human cancer and inhalation exposure to
isoprene speciﬁcally (NTP, 2014). Although there are currently no
human studies that indicate isoprene exposure may increase the
risk of cancer, the USEPACancer Guidelines (USEPA, 2005a) indicate
as a matter of public health-protective policy that positive effects in
animal cancer studies are a basis for assessing the carcinogenic
hazard to humans (in the absence of human data), and laboratory
animal studies are available to quantify the relationship between
animal tumors and isoprene exposure via inhalation. More specif-
ically, three animal studies contain the data necessary to perform
doseeresponse modeling for tumors induced by inhalation expo-
sure to isoprene and are considered below (NTP, 1994, 1999; Placke
et al., 1996). Additional details on these animal studies and
methods utilized for the doseeresponse assessment (e.g., BMD
modeling) are provided below.3. Carcinogenic assessment
The following sections discuss key steps in the carcinogenic
assessment of isoprene and development of the URF. Consistent
with Fig. 1-2a of TCEQ (2015), the key steps are generally as follows:
 Conduct literature review and solicit information from inter-
ested parties.
 Perform carcinogenic weight of evidence (WOE) and mode of
action (MOA) analyses (linear low-dose extrapolation is the
default for a mutagenic or unknown MOA).
 Identify key studies with sufﬁcient information to conduct
doseeresponse analyses (only animal study cancer data are
sufﬁcient and available for isoprene inhalation exposure).
 Conduct doseeresponse modeling with the best methods
available to derive a POD (e.g., LEC10 from BMD modeling).
 Calculate the URF (e.g., 0.1/LEC10 ¼ URF).
The ﬁrst two steps shown above (i.e., literature search, carci-
nogenic WOE andMOA analyses) are inherently part of the process,
but need not be discussed in detail here since the focus of this paper
is on documentation of the doseeresponse analyses and methods
used in the URF derivation process. The ﬁrst step was initially
conducted by the TCEQ in 2012, and a new scientiﬁc literature
search (through July 2015) did not reveal additional studies for
doseeresponse modeling. In regard to the second step, a carcino-
genic WOE analysis has recently been conducted by NTP (2014) and
concluded that isoprene is “reasonably anticipated to be a human
carcinogen”, and an MOA analysis would not likely result in a de-
parture from the linear, low-dose extrapolation approach
employed in this study (e.g., although Placke et al., 1996 indicated
that a threshold effect level appeared to exist for tumor develop-
ment, like 1,3-butadiene, the diepoxide intermediates of isoprene
have the ability to cause mutations and there is a lack of sufﬁcient
carcinogenic MOA data to justify an alternative approach). Conse-
quently, the following sections focus on the last three steps shown
above.
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No human studies have evaluated the relationship between
human cancer and inhalation exposure to isoprene speciﬁcally
(NTP, 2014). Consequently, the three laboratory animal studies
available for tumor doseeresponse modeling were considered for
URF development (NTP, 1994, 1999; Placke et al., 1996). An over-
viewof the experimental designs for these three studies is provided
in Table 1.
3.1.1. NTP (1994)
This NTP isoprene inhalation toxicity study in F344/N rats and
B6C3F1 mice was a combination of a dose-ﬁnding, subacute study
and two chronic studies. For the relevant chronic stop-exposure
study portion, groups of 40 male rats and 40 male mice were
exposed to 0, 70, 220, 700, 2200, or 7000 ppm isoprene for 6 h/day,
5 days/week, for 6 months. Ten animals per species were evaluated
at the end of the exposure while the rest were allowed to recover
for an additional 6 months without isoprene exposure. Since the
objective of the doseeresponse assessment for the URF is to char-
acterize chronic carcinogenesis, observations made at 6 months
were not included in the doseeresponse analysis, only those at 12
months. Interstitial cell hyperplasia of the testis was observed in
male rats exposed to 7000 ppm isoprene, and after 6 months of
recovery the incidence of benign testicular adenomas was
marginally greater than controls. In the mice, the incidences of
several effects were found to be signiﬁcantly greater than controls.
Table 2 provides tumor data for the target organs for which the NTP
(1994) study indicated at least one statistically signiﬁcantly
increased tumor response rate compared to controls.
No malignancies occurred in rats, and in mice no malignancy
had a statistically increased incidence over controls in any dose
group for any target organ (e.g., liver and lung are most directly
relevant to humans). This is consistent with the lack of a strong
doseeresponse for the mouse liver and lung carcinomas. For
example, while liver carcinoma had a statistically signiﬁcant trend
and the strongest doseeresponse among malignancies, only 4 mice
in the 2200 ppm exposure group developed this carcinoma, the
same number of animals with liver carcinoma in the control group.
Consequently, these data were not considered further for devel-
opment of a URF since:
 URFs are for the estimation of carcinogenic risk;
 A cancer doseeresponse assessment should include malig-
nancies relevant to humans that are statistically signiﬁcantly
increased (compared to controls) for at least one dose in study
animals (TCEQ, 2015);
 No dose group had a malignancy with a statistically increased
incidence over controls; and
 The data appear inadequate to deﬁne a doseeresponse curve for
cancer at the lower study doses (e.g., 2200 ppm for liver car-
cinoma), which is of particular importance for assessing po-
tential human cancer risk.Table 1
Overview of the experimental designs for the animal studies used for doseeresponse m
Study Species Gender Exposure levels (ppm) Ex
ho
NTP (1994) F344/N rats males 0, 70, 220, 700, 2200, 7000 6
NTP (1994) B6C3F1 mice males 0, 70, 220, 700, 2200, 7000 6
NTP (1999) F344/N rats males 0, 220, 700, 7000 6
NTP (1999) F344/N rats females 0, 220, 700, 7000 6
Placke et al. (1996) B6C3F1 mice males 0, 10, 70, 140, 280, 700, 2200 4 o
Placke et al. (1996) B6C3F1 mice females 0, 10, 70 8Lastly, as discussed later in Section 3.1.3, liver carcinoma was
statistically increased over controls in several dose groups in the
Placke et al. (1996) study, and it is noted that the POD (e.g., LEC10)
for the NTP (1994) and Placke et al. (1996) liver carcinoma data
combined would be very similar to that based on the more robust
Placke et al. liver carcinoma dataset (data not shown).
3.1.2. NTP (1999)
In this NTP toxicology and carcinogenesis study of isoprene,
groups of 50 male and 50 female F344/N rats were exposed to 0,
220, 700, or 7000 ppm isoprene for 6 h/day, 5 day/week, for 105
weeks (Table 1). The incidences of tumors in several organs were
found to be signiﬁcantly greater than in controls. Table 3 provides
tumor data for the target organs for which the NTP (1999) study
indicated at least one statistically signiﬁcantly increased tumor
response rate compared to controls.
No malignancy had a statistically increased incidence over
controls in any dose group for any target organ (e.g., kidney,
mammary gland). This is consistent with the lack of a dos-
eeresponse for kidney and mammary gland carcinomas in male
and female rats, respectively, and the lack of a strong dos-
eeresponse for mammary gland carcinoma in male rats (e.g., the
trend was not statistically signiﬁcant). Similar to NTP (1994), the
data appear inadequate to deﬁne a doseeresponse curve for cancer.
Consequently, for the same reasons cited for NTP (1994) (see Sec-
tion 3.1.1), these data were not considered further for development
of a URF.
3.1.3. Placke et al. (1996)
Placke et al. (1996) was a chronic inhalation study in B6C3F1
mice that investigated the effects of various concentrations and
durations of exposure to isoprene (results are also discussed in Cox
et al., 1996). The study design is summarized in Table 4. Of the 15
exposure groups, two were control groups and thirteen groups of
mice were dosed. The incidences of tumors in multiple organs were
found to be signiﬁcantly greater than controls. Table 5 provides
data for the target organs for which the Placke et al. (1996) study
indicated at least one statistically signiﬁcantly increased tumor
response rate compared to controls.
Only the liver, lung, and hematopoietic system had dose groups
for which malignancies had statistically increased incidence over
controls. However, the malignancies of the lung (carcinoma) and
hematopoietic system (histiocytic sarcoma) had weak/poor dos-
eeresponse relationships. For example, while lung carcinoma in
male mice had a statistically signiﬁcant trend, and mice exposed to
700 and 2200 ppm isoprene for 8 h/day over 80 weeks had a sta-
tistically increased incidence over controls, the incidences at these
two high exposure levels were relatively low (both 7/50), with
280 ppm for 8 h/day over 80 weeks inducing only a single lung
carcinoma in 50 animals (1/50) (Table 5). By comparison, 280 ppm
for 8 h/day over 80 weeks induced a much higher incidence of liver
carcinoma (16/50). Histiocytic sarcoma in male mice also had a
statistically signiﬁcant trend with mice exposed to 280 ppm (8 h/odeling.
posure duration Time of response observation/necropsy
urs/day days/week weeks weeks
5 26 53
5 26 53
5 105 106
5 105 106
r 8 5 20, 40, or 80 96 or 105
5 80 105
Table 2
Target organs with statistically signiﬁcant increased responses in the NTP (1994) study.
Exposure level (ppm) 0a 70 220 700b 2200 7000
Target organ Response
Male F344/N Rats
Testis Number at Risk 30 30 30 30 29 30
Adenoma 3* 3 4 7 8 9
Male B6C3F1 Mice
Liver Number at Risk 30 30 29 30 30 28
Adenoma 4** 2 6 15* 18* 16*
Carcinoma 4** 1 3 5 4 9
Adenoma/Carcinoma 7** 3 7 15** 18** 17**
Lung Number at Risk 30 30 29 30 30 28
Adenoma 2** 2 1 4 10* 8*
Carcinoma 0** 0 0 1 1 3
Adenoma/Carcinoma 2** 2 1 5 10* 9*
Forestomach Number at Risk 30 30 30 30 30 30
Papilloma 0** 0 0 1 2 5*
Carcinoma 0 0 0 0 2 1
Papilloma/Carcinoma 0** 0 0 1 4 6**
Harderian Gland Number at Risk 30 30 30 30 30 30
Adenoma 2** 6 4 14** 13** 12**
Carcinoma 0 0 0 0 1 0
Adenoma/Carcinoma 2** 6 4 14** 13** 12**
*Statistically signiﬁcant at the 5% signiﬁcance level.
**Statistically signiﬁcant at the 1% signiﬁcance level.
a Statistically signiﬁcant results in the control group are for the Cochran-Armitage trend test for an increasing trend.
b Statistically signiﬁcant results in the exposed groups are for the Fisher exact test for an increase in the incidence versus the incidence in the control group.
Table 3
Target organs with statistically signiﬁcant increased responses in the NTP (1999) study.
Exposure level (ppm) 0a 220b 700 7000
Number of animals at risk 50 50 50 50
Target organ Response
Male F344/N Rats
Kidney Adenoma 2** 4 8* 15**
Carcinoma 0 0 1 0
Adenoma/Carcinoma 2** 4 8* 15**
Mammary Gland Fibroadenoma 2** 4 6 21**
Carcinoma 0 1 1 2
Fibroadenoma/Carcinoma 2** 5 7 21**
Testis Adenoma 33** 37 44** 48**
Female F344/N Rats
Mammary Gland Fibroadenoma 19 35** 32** 32**
Carcinoma 4 2 1 3
Fibroadenoma/Carcinoma 20 35** 32* 32*
*Statistically signiﬁcant at the 5% signiﬁcance level.
**Statistically signiﬁcant at the 1% signiﬁcance level.
a Statistically signiﬁcant results in the control group are for the Cochran-Armitage trend test for an increasing trend.
b Statistically signiﬁcant results in the exposed groups are for the Fisher exact test for an increase in the incidence versus the incidence in the control group.
Table 4
Experimental design for the Placke et al. (1996) study in B6C3F1 mice.
Exposure group Gender Time of response observation/necropsy Exposure level (ppm) Hours/day Days/week Weeks
1 Male 105 weeks 280 8 5 20
2 Male 105 weeks 2200 4 5 20
3 Male 105 weeks 70 8 5 40
4 Male 105 weeks 140 8 5 40
5 Male 105 weeks 2200 8 5 40
6 Male 105 weeks 0 8 5 80
7 Male 96 weeks 10 8 5 80
8 Male 96 weeks 70 8 5 80
9 Male 96 weeks 280 8 5 80
10 Male 96 weeks 700 8 5 80
11 Male 96 weeks 2200 8 5 80
12 Male 96 weeks 2200 4 5 80
13 Female 105 weeks 0 8 5 80
14 Female 105 weeks 10 8 5 80
15 Female 105 weeks 70 8 5 80
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Table 5
Target organs with statistically signiﬁcant increased responses in the Placke et al. (1996) study.
Exposure level (ppm) 0a 10b 70 70 140 280 280 700 2200 2200 2200 2200
Exposure duration (weeks) 80 80 40 80 40 20 80 80 20 80 40 80
Daily exposure (hours/day) 8 8 8 8 8 8 8 8 4 4 8 8
Target organ Response
Male B6C3F1 Mice
Liverc Number at Risk 50 50 49 50 50 49 50 48 50 50 47 50
Adenoma 11** 12 14 15 22* 18 24** 27** 22* 21* 28** 30**
Carcinoma 9** 6 11 9 10 12 16 17* 12 15 18* 16
Adenoma/Carcinoma 20** 18 25 24 32* 30* 40** 44** 34** 36** 46** 46**
Lungc Number at Risk 50 50 50 50 50 50 50 50 50 50 49 50
Adenoma 11** 16 8 4 10 16 13 23** 14 15 29** 30**
Carcinoma 0** 1 0 2 1 3 1 7** 2 3 3 7**
Adenoma/Carcinoma 11** 17 8 6 11 19 14 30** 16 18 32** 37**
Hematopoietic System Number at Risk 50 50 50 50 50 50 50 50 50 50 50 50
Histiocytic Sarcoma 0** 2 2 2 1 8** 4 2 5** 7** 7** 2
Any Lymphoma 2** 1 2 4 1 7 5 4 4 4 5 6
Heart Number at Risk 49 50 49 50 50 50 50 50 50 50 49 50
Hemangiosarcoma 0** 0 0 0 0 0 2 1 4 1 1 1
Spleen Number at Risk 49 48 47 50 50 47 50 48 48 50 47 49
Hemangiosarcoma 1 3 1 2 3 2 1 2 2 2 0 1
Forestomachc Number at Risk 50 48 47 50 49 46 50 47 48 50 47 50
Papilloma 0** 0 0 0 0 0 0 1 0 1 2 1
Carcinoma 0** 0 0 0 0 0 1 0 1 1 0 3
Papilloma/Carcinoma 0** 0 0 0 0 0 1 1 1 2 2 4
Harderian Glandc Number at Risk 47 49 48 50 50 49 50 49 49 50 49 50
Adenoma 4** 4 13* 9 12* 16** 17** 26** 19** 28** 31** 35**
Carcinoma 0 0 0 0 2 3 1 3 1 2 0 2
Adenoma/Carcinoma 4** 4 13* 9 14* 19** 18** 29** 20** 30** 31** 37**
Female B6C3F1 Mice
Spleen Number at Risk 50 49 e 50 e e e e e e e e
Hemangiosarcoma 1* 1 e 4 e e e e e e e e
Pituitary Gland Number at Risk 49 46 e 49 e e e e e e e e
Adenoma 1* 6* e 9** e e e e e e e e
Harderian Glandc Number at Risk 49 49 e 49 e e e e e e e e
Adenoma 2* 3 e 8* e e e e e e e e
Carcinoma 0 0 e 0 e e e e e e e e
Adenoma/Carcinoma 2* 3 e 8* e e e e e e e e
*Statistically signiﬁcant at the 5% signiﬁcance level.
**Statistically signiﬁcant at the 1% signiﬁcance level.
a Statistically signiﬁcant results in the control group are for the Cochran-Armitage trend test for an increasing trend.
b Statistically signiﬁcant results in the exposed groups are for the Fisher exact test for an increase in the incidence versus the incidence in the control group.
c The combined responses papilloma/carcinoma and adenoma/carcinoma are the sums of the two individual responses since Placke et al. did not report these responses
combined.
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day for 40 weeks) having statistically increased incidences over
controls. However, even the statistically increased incidences at
2200 ppm were relatively low (5/50 to 7/50 for the various expo-
sure regimens). In fact, the incidences at 2200 ppmwere lower than
the statistically increased incidence at 280 ppm (8/50). Addition-
ally, the incidence at 700 ppm (2/50) was 2e4 times less than the
incidences at 280 ppm (Table 5). Thus, these malignancies (i.e., lung
carcinoma, histiocytic sarcoma) do not provide particularly robust
datasets for doseeresponse assessment and the associated data for
these cancer endpoints are not discussed further in any detail.
Considering the malignant endpoints reported in Placke et al.
(1996), the mouse liver is the best target organ upon which to
base a carcinogenic doseeresponse assessment. That is, the dos-
eeresponse data for liver carcinoma in male B6C3F1 mice provide
the best basis (i.e., most robust dataset) for the quantiﬁcation of the
relationship between cancer and isoprene inhalation exposure and
derivation of a URF. Liver carcinoma had a statistically signiﬁcant
trend with male mice exposed to 700 ppm (8 h/day for 80 weeks)
and 2200 ppm (8 h/day for 40 weeks, although the incidence for
80-week exposure was very similar) having statistically increased
incidences over controls. The incidences at these doses (17/48 and
18/47) are appreciably higher than the highest incidences at the
same exposure levels for lung carcinoma (7/50 for both exposure
levels) and histiocytic sarcoma (2/50 and 7/50, respectively)(Table 5). Additionally, while the incidence of liver carcinoma at
280 ppm was not statistically signiﬁcantly increased over controls,
it was still relatively high (e.g., 16/50 at 280 ppm for 8 h/day over 80
weeks).
As the doseeresponse for liver carcinoma is stronger than that
for lung carcinoma or histiocytic sarcoma, it ultimately provides a
POD (i.e., LEC10) that is approximately 2e3 times lower than those
for the two other cancer endpoints (data not shown). Consequently,
the URF is more conservative (i.e., may be more health protective)
as it results in a lower acceptable lifetime average air concentration
at a given risk level within USEPA's acceptable excess risk range
(1E-06 to 1E-04). Thus, the URF for assessing carcinogenic risk will
be based on the most robust dataset and conservative malignant
endpoint in the Placke et al. (1996) study, liver carcinoma in male
B6C3F1 mice.3.2. Adjustments to the exposure levels and number of animals at
risk
URFs estimate excess risk per unit of lifetime average air con-
centration (e.g., excess risk per ppb of the lifetime average air
concentration) assuming that exposure is 24 h/day, 7 days/week,
for a lifetime. Consistent with this assumption, the exposure levels
and numbers of animals at risk in Placke et al. (1996) were adjusted
for differences between the exposure durations and times of
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for 24 h/day, 7 days/week, for a lifetime (assumed environmental
exposure). Details are provided in the following sections.3.2.1. Adjusted exposure levels based on the multistage theory of
carcinogenesis
The Armitage and Doll (1954) mathematical description of
carcinogenesis as expressed by Crouch (1983), Crump and Howe
(1984), and several others allows for the analysis of datasets with
variable dosing over time. The model assumes that cancer derives
from a single cell after it has undergone a series of transformations.
The model has been used to describe cancer dose-response data in
animal bioassays as well as in the general population. Assumptions
are required for application of the Armitage-Doll model regarding:
(1) the mathematical relationship between applied dose and the
probability that a “stage transition” has occurred; (2) the stage
affected by the carcinogen; and (3) the number of stages.
The multistage theory of carcinogenesis assumes that the
transformation of a normal cell to a speciﬁed neoplastic stage re-
quires the occurrence of “m” biological events (transitions) and that
these events occur in a speciﬁc order. Mathematically, if li is the
transition rate for a cell from the ith stage to the i þ 1st stage in an
m-stage carcinogenic process (i ¼ 0, 1, 2,…, m-1 and i ¼ 0 corre-
sponds to the normal or background stage), then the hazard rate
H(Te) corresponding to a single cell leading to the speciﬁed
response (tumor) occurring by a speciﬁed time Te under Armitage
and Doll (1954) becomes
HðTeÞ ¼
ZTe
0
lm1 
Ztm1
0
lm2 
Ztm2
0
lm3 …

Zt1
0
l0dt0dt1… dtm2dtm1
This corresponds to an (m-1)-stage cell having to make the ﬁnal
transition to the mth stage at some time t(m-1) between time 0 and
time Te, preceded by an (m-2)th stage cell having to make a tran-
sition to the (m-1)th stage at some time t(m-2) between time 0 and
time t(m-1), and so forth back to a normal (0th stage) stage cell
having tomake a transition to the 1st stage at some time t0 between
time 0 and time t1 (also see Crump and Howe, 1984; Kodell et al.,
1987; or Holland and Sielken, 1993). Therefore, if there are “N”
independent normal cell lines, the probability of developing cancer
by age Te is the probability of at least one of these cell lines reaching
the mth stage, that is, P(Te) ¼ 1 e exp[eN  H(Te)].
In the special case where li is independent of time and linearly
dependent on dose, then
li ¼ ai þ bi  d
and
PðTeÞ ¼ 1 eN½ða0þb0dÞða1þb1dÞ…ðam1þbm1dÞðTeÞ
m=m!
or, equivalently
PðTeÞ ¼ 1 e½q0þq1dþq2d2þ…þqmdm
This is commonly referred to as the multistage model or the
Armitage-Doll multistage model.
If li is linearly dependent on dose and dose is dependent on
time, say d(t), but li is otherwise independent of time thenli ¼ liðtÞ ¼ ai þ bi  dðtÞ
and
HðTeÞ ¼
ZTe
0
lm1 
Ztm1
0
lm2 
Ztm2
0
lm3 …

Zt1
0
l0 dt0dt1… dtm2dtm1
depends onwhich speciﬁc li are time dependent and the functional
form of d(t). In particular, if only l0 is dose dependent and
dðtÞ ¼
8<
:
0 for t < a
d for a  t  b
0 for t >b
then the extra risk at time Te for this situation is equal to the extra
risk at time T corresponding to the end of a normal lifetime at a
constant dose D from time 0 to time T when
D ¼ d  {[Te e a]m e [Te e b]m}/Tm.
That is, the extra risk at time Te with intermittent dose d(t) (i.e.,
{P[Te, d(t)] e P[Te, 0]}/P[Te, 0]) equals the extra risk at time T with a
constant dose D (i.e., {P[T, D] e P[T, 0]}/P[T, 0]). In this sense the
constant dose D is equivalent to the time-dependent dose d(t).
Accordingly, for doseeresponse modeling the intermittent
experimental doses d(t) in Placke et al. (1996) were transformed to
equivalent doses D prior to using BMD software to estimate POD
(i.e., EC10/LEC10) values in units of D (i.e., constant environmental
ppm). This same equivalence is alluded to and used in both OEHHA
(2004) and OEHHA (2010). The equivalent constant doses (D) are
for speciﬁed values of m (i.e., the number of biological events
required for transformation) where i ¼ 1 (i.e., the only transition
rate that is dose-dependent is the ﬁrst transition rate which is from
the normal stage to the ﬁrst stage), Te ¼ 104, T ¼ 104, a ¼ 0, and b
equals the number of weeks of exposure (note that Te ¼ 104 and
T ¼ 104 correspond to a 2-year mouse lifetime). Adjusting the
formula for D to account for the assumption that “d” is the 24 h/day,
7 days/week dose, the formula for D becomes
D ¼ d ðnhrs=24Þ  ðndays=7Þ 
ðTe  aÞm  ðTe  bÞmTm
where:
D ¼ equivalent lifetime average daily dose
d ¼ experimental dose
nhrs ¼ hours of exposure/day
ndays ¼ days of exposure/week
Te ¼ total study duration (weeks)
T ¼ time (weeks) corresponding to the end of a normal lifetime
(e.g., 104 weeks for mice)
a ¼ time when exposure begins (weeks)
b ¼ time when exposure ends (weeks)
m¼ the number of stages in themultistage carcinogenic process
This formula was used to adjust the study doses to equivalent
continuous lifetime doses by accounting for study exposure dura-
tion, hours/day, and days/week. For example, for the male mice in
Placke et al. (1996) exposed to 10 ppm for 8 h/day, 5 days/week,
Te ¼ 104 weeks, T ¼ 104 weeks, a ¼ 0, and b ¼ 80 weeks, the
equivalent constant dose D (24 h/day, 7 days/week) for a nominal
lifetime (104 weeks) is
Table 6
Study exposure levels adjusted to continuous levels for male B6C3F1 mice in Placke et al. (1996).
Exposure
level (ppm)
Weeks Hours/
day
Time of response
observation/necropsy
(weeks)
m ¼ 1 m ¼ 2 m ¼ 3
Armitage-Doll adjusted continuous
exposure levela (ppm)
Armitage-Doll adjusted continuous
exposure levela (ppm)
Armitage-Doll adjusted continuous
exposure levela (ppm)
0 80 8 105 0.00 0.00 0.00
10 80 8 105 1.83 2.25 2.35
70 40 8 105 6.41 10.36 12.78
70 80 8 105 12.82 15.78 16.46
140 40 8 105 12.82 20.71 25.57
280 20 8 105 12.82 23.18 31.54
280 80 8 96 51.28 63.12 65.85
700 80 8 96 128.21 157.79 164.62
2200 20 4 96 50.37 91.05 123.90
2200 80 4 96 201.47 247.96 258.69
2200 40 8 96 201.47 325.44 401.74
2200 80 8 96 402.93 495.91 517.37
a Adjusted ppm for the experimental exposure duration (b ¼ 20, 40 or 80 weeks), weekly (5 days/week) and daily (4 or 8 h/day) exposure to calculate an equivalent
continuous exposure for an entire lifetime (Te and T ¼ 104 weeks), 7 days/week, and 24 h/day using the Armitage-Doll adjustment for a 1-, 2- and 3-stage multistage
carcinogen affecting the ﬁrst stage (m ¼ 1, 2, or 3).
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ðTe  aÞm  ðTe  bÞmTm
¼ 10 ð8=24Þ  ð5=7Þ  ð104 0Þm  ð104 80Þm104m
¼ 1:83 ppm for m ¼ 1; ¼ 2:25 ppm for m ¼ 2; and
¼ 2:35 ppm for m ¼ 3
Table 6 contains the adjusted doses (constant D values in ppm)
for male B6C3F1 mice in the Placke et al. (1996) study as the critical
cancer endpoint (liver carcinoma) occurred in male mice. Not sur-
prisingly, this adjustment appreciably decreases the study exposure
levels associated with the incidences of the critical cancer endpoint
(liver carcinoma).
3.2.2. Adjusted numbers of subjects at risk based on the multistage
theory of carcinogenesis
If the end of a study (Tend) is not equal to the end of a nominal
lifetime (T), then the number of subjects at risk of developing the
speciﬁed response by the end of a nominal lifetime in the dos-
eeresponse modeling can be adjusted for this inequality. If
m ¼ the number of stages in the multistage carcinogenic
process,
nat risk(i) ¼ the number of subjects in the ith dose group at the
start of the study,
nresp(i) ¼ the number of subjects in the ith dose group that are
observed to have the speciﬁed response by the end of the study
(Tend), and
T ¼ end of a nominal lifetime,
then, if Tend  T, the adjusted number of subjects at risk in the ith
dose group in the doseeresponse modeling is
Adjusted nat riskðiÞ ¼ nrespðiÞ þ

nat riskðiÞ nrespðiÞ
 ðTend=TÞm:
This adjusted number of subjects at risk in the ith dose group
equals the number of subjects that were observed to have the
speciﬁed response by the end of the study (Tend) (these subjects
obviously had sufﬁcient time to develop the speciﬁed response)
plus a proportional change in the number of subjects [nat
risk(i)  nresp(i)] in the ith dose group that did not develop the
speciﬁed response by the end of the study but might have devel-
oped the speciﬁed response if they had been at risk for a little
longer period of time (i.e., from Tend to T). The adjustment factor
(Tend/T)m follows from the mathematics of the multistage model ofcarcinogenesis. As an example, if there were 50 animals put on test
in the ith dose group, 20 animals developed the speciﬁed response
by the end of the experiment at Tend ¼ 78 weeks, and the nominal
lifetime is 104 weeks, then the adjusted number of subjects at risk
would be…
20þ ð50 20Þ  ð78=104Þm ¼ 42:5 for m ¼ 1 and
¼ 36:875 for m ¼ 2:
In the case where Tend > T, the adjusted number of subjects at
risk in the ith dose group in the doseeresponse modeling is
Adjusted nat riskðiÞ ¼ nrespðiÞ  ðTend=TÞm þ

nat riskðiÞ nrespðiÞ

:
This adjusted number of subjects at risk in the ith dose group
equals the number of animals that did not develop the speciﬁed
response by Tend > T plus the adjusted number of subjects that were
observed to have the speciﬁed response by the end of the study
(Tend) (these subjects were at risk for more than a nominal lifetime
response and each effectively represented slightly more than 1
lifetime at risk). If Tend is greater than T so that the number of re-
sponses is greater than it might have been if the end of the study
was shortened to T, then the adjusted number of subjects at risk
would be increased. For example, if there were 50 animals put on
test in the ith dose group, 20 animals developed the speciﬁed
response by the end of the experiment at Tend¼ 130 weeks, and the
nominal lifetime is 104 weeks, then the adjusted number of sub-
jects at risk would be
20 ð130=104Þm þ ð50 20Þ ¼ 55 for m ¼ 1 and
¼ 61:25 for m ¼ 2:
In summary, if the end of a study (Tend) is not equal to the end of
a nominal lifetime (T), then the number of subjects at risk of
developing the speciﬁed risk by the end of a nominal lifetime in the
doseeresponse modeling can be adjusted for this inequality.
Table 7 contains the adjusted number of male B6C3F1 mice at
risk for liver carcinoma in the Placke et al. (1996) study since
the critical cancer endpoint (liver carcinoma) occurred in male
mice. This adjustment results in negligible changes for some
exposure groups (e.g., 10e140 ppm groups) while reducing the
number of animals at risk in others, which somewhat increases
the incidence of liver carcinoma in these groups as the denominator
is smaller. For example, with m ¼ 3, the incidence in the 2200 ppm
group exposed 8 h/day over 40 weeks increases from 38% (18/47)
Table 7
Dose-response data for liver carcinoma in male B6C3F1 mice from Placke et al. (1996).
Exposure Level (ppm) 0a 10 70 70 140 280 280 700b 2200 2200 2200 2200
Exposure Duration (weeks) 80 80 40 80 40 20 80 80 20 80 40 80
Daily Exposure (hours/day) 8 8 8 8 8 8 8 8 4 4 8 8
Adjusted Exposure Level: m ¼ 1
(ppm)c
0.00 1.83 6.41 12.82 12.82 12.82 51.28 128.21 50.37 201.47 201.47 402.93
Adjusted Exposure Level: m ¼ 2
(ppm)c
0.00 2.25 10.36 15.78 20.71 23.18 63.12 157.79 91.05 247.96 325.44 495.91
Adjusted Exposure Level: m ¼ 3
(ppm)c
0.00 2.35 12.78 16.46 25.57 31.54 65.85 164.62 123.90 258.69 401.74 517.37
Observation Time (weeks) 105 105 105 105 105 105 96 96 96 96 96 96
Liver Number at Risk 50 50 49 50 50 49 50 48 50 50 47 50
Adjusted# at Risk: m ¼ 1 50.1 50.1 49.1 50.1 50.1 49.1 47.4 45.6 47.1 47.3 44.8 47.4
Adjusted# at Risk: m ¼ 2 50.2 50.1 49.2 50.2 50.2 49.2 45.0 43.4 44.4 44.8 42.7 45.0
Adjusted# at Risk: m ¼ 3 50.3 50.2 49.3 50.3 50.3 49.3 42.7 41.4 41.9 42.5 40.8 42.7
Carcinoma 9** 6 11 9 10 12 16 17* 12 15 18* 16
*Statistically signiﬁcant at the 5% signiﬁcance level.
**Statistically signiﬁcant at the 1% signiﬁcance level.
a Statistically signiﬁcant results in the control group are for the Cochran-Armitage trend test for an increasing trend.
b Statistically signiﬁcant results in the exposed groups are for the Fisher exact test for an increase in the incidence versus the incidence in the control group.
c From Table 6.
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3.3. Dose-response modeling
Table 7 contains all the data necessary for doseeresponse
modeling of liver carcinoma: the adjusted number of mice at risk
for liver carcinoma in Placke et al. (1996); the number of animals
with liver carcinoma (from Table 5); and study exposure levels that
have been adjusted for continuous exposure (from Table 6). The
multistage cancer model (USEPA BMD Software Version 3.4) was
used to estimate POD (i.e., EC10/LEC10) values for derivation of the
URF (e.g., 0.1/LEC10 ¼ URF). Three forms of the doseeresponse data
were ﬁt by the multistage model. The three forms of the data
correspond to the three forms of the adjusted exposure levels and
the three forms of the adjusted numbers of animals at risk. That is,
the three forms correspond to: (1) m ¼ 1 with one transition rate
from a normal cell to a ﬁrst-stage (tumor) cell; (2) m ¼ 2 with one
transition rate from a normal cell to a ﬁrst stage cell and a second
transition rate from a ﬁrst-stage cell to a second-stage (tumor) cell;
and (3) m ¼ 3 with one transition rate from a normal cell to a ﬁrst
stage cell, a second transition rate from a ﬁrst-stage cell to a
second-stage cell, and a third transition rate from a second-stage
cell to a third-stage (tumor) cell. Again, the doseeresponse
modeling was conducted with the experimental doses adjusted to
the constant lifetime environmental dose D (ppm) that is equiva-
lent to the time-dependent dose d(t), as described in Section 3.2.1
and provided in Tables 6 and 7, and with the experimental
numbers of animals at risk adjusted to the equivalent number of
animals at risk if the time to necropsy (Te) were equal to the
nominal animal lifetime (T), as described in Section 3.2.2 and
provided in Table 7.
Figs. 1e3 were provided by the BMD software (version 3.4) and
show ﬁts of the multistage models to the three forms of the liver
carcinoma doseeresponse data that were ﬁt (i.e., Figs. 1e3 are for
m ¼ 1, 2, and 3, respectively). Satisfactory model ﬁt was conﬁrmed
by a goodness-of-ﬁt p value >0.1 with scaled residuals <j2j. These
ﬁgures show that the ﬁttedmultistagemodels are nearly linear. The
ﬁtted multistage models are used by the BMD software to estimate
the EC corresponding to 10% extra risk (EC10) and the LEC10 in units
of a constant environmental ppm. The LEC10 is estimated by the
BMD software using the “standard default” procedure that de-
termines the ﬁt of the multistage model with the largest slope that
is not statistically detectable as a bad ﬁt. The EC10 and LEC10 values
for liver carcinoma are provided in Table 8. The LEC10 is a commonPOD for calculation of a URF. However, for isoprene, interspecies
differences in metabolism and dosimetry should be considered and
accounted for ﬁrst.
3.4. Interspecies differences in metabolism and dosimetry
As stated previously, isoprene has been found to be one of the
main endogenous compounds in human breath, accounting for up
to 70% of exhaled hydrocarbons (Gelmont et al., 1981 as cited by
NTP, 2014). For example, a weighted multiple-study mean of
64 ± 49 ppb has been reported in human volunteers (MAK, 2012).
However, default linear low-dose extrapolation of high-dosemouse
carcinogenicity data obtained at air concentrations tens-of-
thousands to millions of times higher than environmental
isoprene concentrations can result in risk-based air concentration
comparison values (e.g., at the 1E-05 excess risk level) that are
appreciably less than central tendency values for endogenously
produced isoprene present in human breath. This is suggestive of
the potential for a toxicity value (i.e., URF) to unrealistically char-
acterize risk due to long-term environmental isoprene exposure,
which requires further evaluation of conservative default pro-
cedures and consideration of a more chemical-speciﬁc, data-
informed and scientiﬁcally-defensible approach. Based on the data
available for isoprene, two important areas were evaluated for
derivation of POD (LEC10) adjustment factors for a more chemical-
speciﬁc approach:
 Species differences in metabolism; and the
 Dosimetric adjustment factor.3.4.1. Differences in metabolism
The Interagency Pharmacokinetics Group (USEPA, Food & Drug
Administration, Consumer Product Safety Commission) consensus
report by federal scientists on cross-species extrapolation of cancer
(USEPA,1992) indicates that, “… tissues experiencing equal average
concentrations of the carcinogenic moiety over a full lifetime
should be presumed to have equal lifetime cancer risk.” In other
words, equal carcinogenic metabolite concentrations in target tis-
sue (i.e., toxicokinetically-equivalent doses) should be assumed to
yield equal lifetime cancer risks across species at the target organ.
By corollary, appreciably higher or lower lifetime carcinogenic
metabolite concentrations in laboratory animal target tissue
compared to humans are indicative of species differences in
Fig. 1. Model Fit to Male Mouse Liver Carcinoma Data with m ¼ 1.
Fig. 2. Model Fit to Male Mouse Liver Carcinoma Data with m ¼ 2.
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experience toxicokinetically-equivalent doses at a given air con-
centration since relevant parameters (e.g., cardiac output, minutevolume of breathing, rate of metabolism) tend to vary across spe-
cies allometrically (e.g., with body weight3/4). However, case-
speciﬁc (e.g., species, chemical, dose) data regarding the
Fig. 3. Model Fit to Male Mouse Liver Carcinoma Data with m ¼ 3.
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from this is indicated (USEPA, 1992). This is the case for isoprene.
The lowest carcinogenic POD in Table 8 (LEC10 of 80.24 ppm) is
based on liver carcinoma in male B6C3F1 mice (with m ¼ 1).
Bogaards et al. (2001) utilized physiologically-based pharmacoki-
netic (PBPK) modeling to predict the liver concentrations of
isoprene metabolites (i.e., isoprene monoepoxides EPOX-I and
EPOX-II, mutagenic isoprene diepoxide) in B6C3F1 mice, Wistar
rats, and humans. While the roles of isoprene metabolites in
carcinogenesis may not be clear (e.g., the suspected toxic metabo-
lite is isoprene diexpoxide), the PBPK predictions of Bogaards et al.
(2001) allow evaluation of the predicted species differences in the
metabolites of isoprene for the species and target organ of interest
for the carcinogenic assessment (i.e., the B6C3F1 mouse and human
livers). Furthermore, the range of air concentrations evaluated by
Bogaards et al. (20e10,000 ppm) provides good coverage of the air
concentrations tested in the key mouse carcinogenicity study
(10e2200 ppm in Placke et al., 1996). Table 9 provides the predicted
concentrations of isoprene metabolites (i.e., isoprene monoep-
oxides EPOX-I and EPOX-II, mutagenic isoprene diepoxide) in the
human and mouse liver (based on Table 5 of Bogaards et al., 2001).Table 8
EC10 and LEC10 values for liver carcinoma in male B6C3F1 mice from Placke et al.
(1996).
Critical cancer endpoint EC10a (ppm) adjusting for
1, 2, or 3 number of stages
LEC10a (ppm) adjusting
for 1, 2, or 3 number of
stages
m ¼ 1 m ¼ 2 m ¼ 3 m ¼ 1 m ¼ 2 m ¼ 3
Liver Carcinoma 126.36 137.55 130.24 80.24 91.18 88.83
a The endpoint was analyzed for three alternative adjustments to the study
exposure levels and numbers of animals at risk (i.e., m ¼ 1, 2, or 3); the exposure
levels were for continuous lifetime environmental exposure.Since the carcinogenic response cannot be attributed to a
particular metabolite at this time, species differences in the pre-
dicted liver concentrations were assessed across these metabolites
(i.e., EPOX-I, EPOX-II, diepoxide). As can be seen from Table 9, the
predictedmouse liver concentrations of isoprenemetabolites range
from approximately 3- to 30-fold higher than those for humans,
depending on the particular metabolite and dose. Themean species
difference is approximately 13-fold for the monoepoxides (EPOX-
I þ EPOX-II) and approximately 25-fold for the carcinogenic
metabolite assumed in the study (isoprene diepoxide), with an
overall mean of about a 17-fold higher liver concentration predicted
for B6C3F1 mice compared to humans. The overall mean species
difference is approximately 14-fold for the dosesmost similar to the
lowest carcinogenic POD (LEC10 of 80.24 ppm in Table 8). Because
unequal target tissue concentrations across species are generally
expected to result in proportionally unequal carcinogenic risk,
these tissue concentration results suggest that humans may be
expected to be less sensitive to isoprene-induced liver carcino-
genesis than mice due to species differences in metabolism
resulting in appreciably lower liver metabolite concentrations
predicted for humans. Considering these results for predicted
species differences in target tissue metabolite concentration and
uncertainty in the data, an order of magnitude POD (LEC10) meta-
bolic adjustment factor (MAF) of 10 appears reasonable and
possibly conservative, especially considering that the diepoxide is
often purported to be the putative carcinogenic metabolite (e.g.,
MAK, 2012; Csanady and Filser, 2001; Placke et al., 1996). Thus, a
MAF of 10was used to adjust the lowest carcinogenic POD in Table 8
(LEC10 of 80.24 ppm based on liver carcinoma in mice) (see Section
3.4.3).
3.4.2. Dosimetric adjustment factor
Isoprene produces both respiratory and remote effects, and is
therefore classiﬁed as a Category 2 gas. Dosimetric adjustments for
Table 9
Predicted concentrations of isoprene metabolites in human and B6C3F1 mouse liver tissue.
Isoprene concentration (ppm) Species PBPK-predicted liver metabolite concentrationsa Mean Mouse/Human ratio at dose
EPOX-I (mM) Mouse/Human EPOX-II (mM) Mouse/Human Diepoxide (mM) Mouse/Human
20 Mouse 0.065 16.3 0.014 2.8 0.0022 22.0 13.7
Human 0.004 0.005 0.0001
200 Mouse 0.60 17.1 0.14 2.9 0.021 21.0 13.7
Human 0.035 0.049 0.001
2000 Mouse 3.5 23.3 0.91 3.8 0.13 26.0 17.7
Human 0.15 0.24 0.005
10000 Mouse 6.0 30.0 1.8 5.1 0.23 32.9 22.7
Human 0.20 0.35 0.007
Mean Mouse-to-Human Ratio 16.9
a Based on Table 5 of Bogaards et al., 2001.
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dosimetry equations, whichever is relevant to the critical effect
(point-of-entry versus systemic) (TCEQ, 2015). Category 3 is the
relevant classiﬁcation for isoprene-induced liver carcinogenesis, a
remote effect. For Category 3 gases:
PODHEC ¼ PODADJx

Hb=g

A
Hb=g

H
where:
(Hb/g)A ¼ ratio of the blood:gas partition coefﬁcient in animals
(Hb/g)H ¼ ratio of the blood:gas partition coefﬁcient in humans
For isoprene, the blood:gas partition coefﬁcients for mice and
humans are 2.04 and 0.75, respectively (Filser et al., 1996). If the
animal blood:gas partition coefﬁcient is greater than the human
blood:gas partition coefﬁcient, as it is in this case (by 2.7-fold), then
a default value of 1 is used for the dosimetric adjustment factor
(DAF) (USEPA, 1994). However, as previously indicated, in this case
further evaluation of this conservative default procedure is justiﬁed
in consideration of a more chemical-speciﬁc, data-informed
approach. Furthermore, since the PBPK modeling of Bogaards et al.
(2001) used the same blood:air coefﬁcients for humans as for mice,
it is noted that the independent evaluation of these parameters
here does not result in double adjustment.
USEPA's Advances in Inhalation Gas Dosimetry for Derivation of a
Reference Concentration (RfC) and Use in Risk Assessment indicates
that although the default DAF for systemic effects is 1, a fairly robust
PK database shows PBPKmodel-derived DAFs to be1 (see Table 4-
1 of USEPA, 2012). Thus, based on a fairly robust database, the
USEPA concludes that the default may be conservative (i.e., may
underestimate the HEC). USEPA further concludes that there is no
apparent pattern of the relationship between the ratio of the ani-
mal and human blood:gas partition coefﬁcients (i.e., (Hb/g)A/(Hb/
g)H) and the more robust PBPK-derived DAFs that USEPA utilizes as
benchmarks for comparison. However, while this may be true in
regard to a speciﬁc numerical (i.e., quantitative) relationship be-
tween the two, for example, the following relative relationships are
readily apparent upon examination of the underlying analysis in
USEPA's Advances in Inhalation Dosimetry for Gases with Lower
Respiratory Tract and Systemic Effects (see Table 3-13 of USEPA,
2011):
 In cases where (Hb/g)A/(Hb/g)H was equal to 1, the PBPK-derived
DAFs/HECs were approximately 60e700% higher.
 In cases where (Hb/g)A/(Hb/g)H was greater than 1 (i.e., 1.5, 2.3),
the PBPK-derived DAFs/HECs were approximately 4e700%higher than the HECs that would have been calculated based on
the (Hb/g)A/(Hb/g)H ratios.
 Similarly, in the case where (Hb/g)A/(Hb/g)H was less than 1 (i.e.,
0.7), the PBPK-derived DAF/HEC showed that use of the (Hb/g)A/
(Hb/g)H as the DAF would have been conservative (by >30%).
Thus, based on USEPA's analysis of a fairly robust database, use
of the (Hb/g)A/(Hb/g)H as the DAF is conservative, although the
magnitude of conservativeness varied signiﬁcantly. Where (Hb/g)A/
(Hb/g)H was 1, as is the case for isoprene, use of the default DAF of
1 underestimated the HEC (in comparison to validated PBPK
modeling) in every case, by 1.6- to 10.7-fold. Considering these
results, the (Hb/g)A/(Hb/g)H of 2.7 for isoprene, and associated un-
certainty (e.g., standard deviations (SDs) for the Hb/g values), a DAF
of 2 was used to adjust the POD (LEC10).
3.4.3. Adjustment of the POD
Consistent with the previous sections in which a MAF and DAF
were derived, the lowest carcinogenic POD in Table 8 (LEC10 of
80.24 ppm) was adjusted based on interspecies metabolic and
dosimetric considerations:
Adjusted LEC10 ¼ LEC10 of 80:24 ppmMAF of 10 DAF of 2
¼ 1605 ppm
This is a chemical-speciﬁc, novel approach based on the con-
siderations discussed above, which are speciﬁc to this assessment.
The adjusted LEC10 is used to calculate a URF more relevant to
humans.
3.5. Calculation of the URF and air concentration at the 1 in
100,000 excess risk level
The adjusted LEC10 from Section 3.4.3 was used to calculate the
URF:
URF ¼ 0:1=1605 ppm ¼ 6:2E-05 per ppm
¼ 6:2E-08 per ppb or 2:2E-08 per mg=m3
The corresponding lifetime air concentration at the 1 in 100,000
no signiﬁcant excess risk level is 160 ppb (450 mg/m3) rounded to
two signiﬁcant ﬁgures (e.g., 1E-05/6.2E-08 per ppb ¼ 161.3 ppb). It
is noted that this concentration is above typical isoprene breath
concentrations reported in the scientiﬁc literature (e.g., median of
52 ppb in 344 health fair attendees in Moser et al., 2005; weighted
multiple-study mean of 64 ± 49 ppb in 337 volunteers in MAK,
2012). It is also almost 4400 times lower than the lowest expo-
sure level associated with increased liver carcinoma in B6C3F1 mice
in the key study (700 ppm in Placke et al., 1996).
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centration (160 ppb) is 3.4-fold lower than the environmental air
concentration (538 ppb) estimated to correspond to the SD
(2.8 mmol  h/L) of the mean endogenous isoprene blood AUC
(3.6 ± 2.8 mmol  h/L) based on data presented in the MAK (2012)
analysis (calculations not shown), which utilized a PBPK model
validated with experimental human data (Csanady and Filser,
2001). That is, continuous lifetime environmental exposure to the
1 in 100,000 excess risk level of 160 ppbwould be expected to raise
the blood isoprene AUC less than one-third of the SD of the
endogenous mean blood AUC. The mean (2005e2014) for ambient
air monitoring sites in Texas is approximately 0.13 ppb, with a range
from not detected to 0.84 ppb (TAMIS).
4. Discussion and conclusions
It was important to conduct a carcinogenic doseeresponse
assessment for inhalation exposure to isoprene since other human
health assessment programs (e.g., IRIS, OEHHA) have yet to do so. In
this paper, a URF for isoprene was developed based on liver carci-
noma as the cancer endpoint. More speciﬁcally, it was based on the
lowest LEC10 for liver carcinoma in the most sensitive gender of
B6C3F1 mice (males) in the Placke et al. (1996) study. Consistent
with the inherent assumption of environmental exposure in use of
URFs (i.e., exposure 24 h/day, 7 days/week, for a lifetime), the
exposure levels and numbers of animals at risk in Placke et al.
(1996) were adjusted for differences between the exposure dura-
tions and times of response observation and the objective of
characterizing exposure for 24 h/day, 7 days/week, for a lifetime
(see Sections 3.2.1 and 3.2.2). Following doseeresponse/BMD
modeling, the POD (i.e., LEC10) was adjusted for species differences
in target tissuemetabolite concentrations and inhalation dosimetry
through application of a MAF and DAF, respectively (see Sections
3.4.1 and 3.4.2). The resulting URF is 6.2E-08 per ppb or 2.2E-
08 per mg/m3.
The corresponding 104, 105, and 106 excess risk air concen-
trations, assuming continuous lifetime exposure, are 1600 ppb
(4500 mg/m3), 160 ppb (450 mg/m3), and 16 ppb (45 mg/m3),
respectively. While the air concentrations corresponding to 104
and 105 excess risk are above typical human breath concentrations
(e.g., weighted multiple-study mean of 64 ± 49 ppb in 337 volun-
teers inMAK, 2012), that corresponding to the 106 excess risk level
(16 ppb) is well below central tendency human breath levels due to
endogenous isoprene production. This suggests that the carcino-
genic doseeresponse assessment and URF contained herein may be
conservative. For example, inhalation exposure intensity (ppm
level) had a greater impact on response frequency than exposure
duration (analysis not shown), and this 106 air concentration
(16 ppb) is almost 44,000 times lower than the lowest exposure
level associated with statistically increased liver carcinoma in
B6C3F1 mice in the key study (700 ppm in Placke et al., 1996).
Lastly, it is noted that continuous lifetime exposure to the air
concentration (160 ppb) corresponding to the 105 no signiﬁcant
excess risk level used by the TCEQ (TCEQ, 2015) would be expected
to raise the human blood isoprene AUC less than one-third of the
SD of the endogenous mean blood AUC. An isoprene air concen-
tration corresponding to1 SD of the endogenousmean blood AUC
would be expected tomake an insigniﬁcant contribution to lifetime
cancer risk (MAK, 2012). By comparison, ambient air monitoring
sites in Texas a range from not detected to 0.84 ppb, with an
approximate mean of 0.13 ppb (TAMIS data for 2005e2014). In
conclusion, this URF for isoprene (6.2E-08 per ppb or 2.2E-08 per
mg/m3) is considered sufﬁciently health-protective for use in pro-
tecting the general public against the potential carcinogenic effects
of chronic exposure to isoprene in ambient air.5. Uncertainty
Uncertainties are an inherent part of doseeresponse assess-
ments. Generally, three areas of uncertainty relate to the develop-
ment of a URF based on animal data:
 Interspecies differences;
 Site concordance; and
 Linear low-dose extrapolation.
There are signiﬁcant species differences in isoprene sensitivity
and metabolism. For example, mice are more sensitive to isoprene
than rats (e.g., see Table 2), and Filser et al. (1996) found that the
rate of isoprene metabolism for mice and rats are about 14 and 8
times faster than in humans, respectively. It is important to adjust
for appreciable interspecies metabolic differences (if possible)
when extrapolating from animals to humans since these differ-
ences lead to interspecies differences in carcinogenic metabolite
concentrations in target tissue (i.e., the liver in this case), and
consequently risk. Failure of a carcinogenic assessment to do so
may result in signiﬁcantly underestimating human risk or over-
estimating human risk, which would have been the case in this
instance had not an MAF been applied. Interspecies dosimetric
differences should also be adjusted for, if possible (e.g., through a
DAF). While there is some uncertainty in the metabolic and dosi-
metric adjustments made, the values selected for the MAF and DAF
are scientiﬁcally justiﬁed and err on the side of conservatism (see
Sections 3.4.1 and 3.4.2), as does the carcinogenicity-based POD
used for URF derivation (i.e., lowest LEC10 for liver carcinoma in the
most sensitive gender of B6C3F1 mice).
Isoprene has been shown to increase the incidences of malig-
nancies (e.g., carcinoma) and other neoplasms at various sites (e.g.,
liver, lung) in mice (e.g., see Table 5). However, no study has been
conducted to replicate the ﬁndings and data of the key study relied
upon for derivation of the URF (Placke et al., 1996). Moreover, there
appears to be appreciable interspecies variability in sensitivity to
isoprene-induced neoplasms (Table 2), and humans could be more
similar in sensitivity to rats than mice (e.g., malignancies were not
statistically increased in rats in NTP, 1994, 1999). Adding to this
uncertainty, there are no reliable epidemiological data available to
help inform whether or not humans develop isoprene-induced
tumors at relevant exposure levels. Consequently, this is an
appreciable area of uncertainty. Additionally, if humans were to
develop isoprene-induced tumors (at least at sufﬁciently high
exposure concentrations for a sufﬁcient duration), it is unknown
whether they would be at the same sites as in mice (or in another
laboratory animal species). However, knowledge of target organ
concordance is not a prerequisite for evaluating the implications of
animal study results for humans (USEPA, 2005a).
In regard to uncertainty surrounding the ability of linear low-
dose extrapolation to realistically predict risk, it is important to
note that isoprene is an endogenously produced chemical. The rates
of endogenous production in humans, rats, and mice are reported
to be 0.15, 1.9, and 0.4 mmol/kg per hour, respectively (Taalman,
1996; Peter et al., 1987; Hartmann and Kessler, 1990). Conse-
quently, isoprene is one of the main endogenous compounds found
in human breath, accounting for up to 70% of exhaled hydrocarbons
(Gelmont et al., 1981 as cited by NTP, 2014). For example, MAK
(2012) reports a weighted multiple-study mean of 64 ± 49 ppb in
337 volunteers (for comparison, annual averages at monitoring
sites in Texas are typically less than 0.5 ppb). The appreciable
endogenous production of isoprene within the body, leading to the
exhalation of signiﬁcant concentrations, along with other evidence
is suggestive of a threshold for isoprene adverse effects. Therefore,
there may be considerable uncertainty in the use of linear low-dose
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mation of carcinogenic risk at much lower environmental doses
(i.e., it may signiﬁcantly overestimate risk). For example, although
the 1 in 100,000 excess risk level concentration (160 ppb) is higher
than central tendency breath concentrations (e.g., median of 52 ppb
in 344 health fair attendees in Moser et al., 2005), it is still almost
4400 times lower than the lowest exposure level associated with
increased liver carcinoma in B6C3F1 mice in the key study
(700 ppm in Placke et al., 1996). Additionally, using doseeresponse
data from Placke et al. (1996), which includes response data for
different inhalation ppm levels (exposure intensity) and different
exposure durations (4 or 8 h/day, 5 days/week, for 20, 40, or 80
weeks), inhalation exposure intensity had a greater impact on
response frequency than exposure duration (analysis not shown).
This is consistent with the ﬁndings of Cox et al. (1996) and Placke
et al. (1996) stating, for example, “A threshold effect level and
strong nonlinearities with respect to concentration appeared to
exist for tumor development in this study.” Thus, actual risk at
environmental concentrations or the air concentration (160 ppb)
estimated to correspond to the 1 in 100,000 excess risk level using
linear low-dose extrapolation could be signiﬁcantly lower and even
as lowas zero. However, as carcinogenicMOAdata are not sufﬁcient
to justify an alternative approach, linear low-dose extrapolation
was used as the default, conservative approach (TCEQ, 2015). Lastly,
in regard to uncertainty in the doseeresponse modeling, the EC10
and LEC10 values showed excellent agreement (i.e., LEC10 values
were within 1.1-fold of each other and within 1.6-fold of their
corresponding EC10 values) regardless of whether the “m” value
was 1, 2, or 3 (Table 8). The URF would have been 4.0E-05 per ppm
(4.0E-08 per ppb or 1.4E-08 per mg/m3) had it been based on the
lowest EC10 value (126.36 ppm) instead of the lowest LEC10 value
(80.24 ppm).
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